Abstract: The present invention relates to methods for prevention and/or treatment of diseases or conditions caused by deficiency in the adult isoform of a given protein wherein said method comprises administering to a patient in need thereof a composition containing NO or at least one compound able to release, induce and/or promote NO formation in cells, said administration resulting in augmenting or restoring the production of the fetal isoform of said protein in said patient.

Abstract: The present invention discloses a series of quaternary nitrogen compounds in which the four groups surrounding nitrogen are (a) one glyceryl portion, (b) two methyl groups and (c) a hydroxy ethyl group. The compound of the present invention is an outstanding moisturizer when applied to skin.

Abstract: The present invention is directed to a method of treating patients with major depression by administering omega-3 fatty acids. These may be administered in a substantially purified form, as part of a pharmaceutical composition, or as part of a larger molecule, e.g., a triacylglycerol, which releases free fatty acid after ingestion by a patient. The present invention is also directed to triacylglycerols which are esterified at the gamma cardon of glycerol to phosphocholine and at either the alpha or beta carbon of glycerol to an omega-3 fatty acid. These “omega-3 phoshatidylcholines” are also used in the treatment of patients with major depression.

Abstract: Antimicrobial compositions having synergistic combinations of octoxyglycerin and at least one other antimicrobial agent in formulations which are more effective than prior art compositions without causing increased irritation to the skin of the average user. In certain embodiments, skin irritation may be minimized by low concentrations of antimicrobials and/or the presence of soothing compounds such as zinc. Preferred embodiments include combinations of octoxyglycerin, a quaternary compound, and at least one other antimicrobial agent. Without being bound to any particular theory, it is hypothesized that the unexpected antimicrobial effectiveness of combinations of octoxyglycerin may result from an enhancement of the permeability of microbes to antimicrobials caused by octoxyglycerin.

Abstract: 3,4,5-trisubstituted aryl nitrone compounds having the formula: where R1-R4 are as defined in the specification are useful as therapeutics for neuropathic pain conditions in mammals.

Abstract: A sport fishing system having: a rod and reel, including fishing line; at least one fishing lure or natural bait; and a controlled released fish attractant for applying to the fishing lure or natural bait. The system may further include an applicator for applying the controlled released fish attractant to the fishing lure or natural bait. In the preferred embodiment, the controlled release fish attractant includes: an attractant and a substantially hydrophobic, film forming release agent.

Abstract: The use of L-carnitine and its alkanoyl devivatives, optionally in the form of a pharmaceutically acceptable salt, as osmotic agents in the preparation of solutions for medical use, particularly for peritoneal dialysis, is described.

Abstract: A fungicidal composition of disinfecting and preserving agents, including at least both an amine and/or quaternary ammonium salt of the general formula 1

Abstract: The present invention relates to a method of inhibiting the growth of killing algae, bacteria, yeast and/or fungi in a recirculating water system which comprises adding to the water a polymeric biguanide and an adjuvant of the Formula (1) or a salt thereof: wherein: R1 is an optionally substituted C8 to C12 or C18 to C22 alkyl group; and R2 and R3 each independently is H or optionally substituted C1-4-alkyl.

Abstract: The present invention is directed to sanitizing compositions or preparations comprising of a combination of an alcohol-based, volatile biocide and an additional low-concentration, non-volatile antimicrobial agent. In one embodiment of the present invention, the sanitizer preparation comprises a surface sanitizing composition or preparation comprised of at least: (1) a biocide comprising a volatile alcohol at a concentration of from greater than or equal to 30% to less than or equal to 70% w/w; and (2) one or more non-volatile antimicrobial agent that is soluble in said alcohol at a concentration of from greater than or equal to 0.001% to less than or equal to 0.1% w/w.

Abstract: The present invention is concerned with antimicrobial compositions suitable for bacteriostatic/bacteriocidal and fungistatic/fungicidal applications. Anticholinergic quaternary amine compounds are not known for their activity as antimicrobial agents, but have been determined as presenting a substantial benefit while exhibiting significantly reduced toxic effects over conventional treatments. Anticholinergic quaternary amine compounds are incorporated in an excipient matrix, at concentrations of from about 0.001% to about 10.0% (within an order of magnitude) either alone or in combination with conventional antifungal/antibacteriological agents. Anticholinergic quaternary amine compounds have antimicrobial pharmaceutical efficacy as well as the ability to enhance, accelerate and assist antimicrobial activity of other conventional preparations.

Abstract: The present invention provides synthetic biological response modifier compositions. The synthetic biologic response modifier (Syn-BRM) composition comprises: 57±20 mg/L 3-hydroxybutyric acid, 125±44 mg/L lactic acid, 155±54 mg/L acetic acid, 1.4±0.5 mg/L creatine, 22±8 mg/L creatinine, 2.5±0.9 mg/L carnitine, 6.8±2.4 mg/L taurine, 20±7 mg/L choline, 815±285 mg/L urea. The compositions may additionally comprise 40±14 mg/L of formic acid. The synthetic biological response modifier compositions modify biological response in vivo demonstrating anti-cancer activity and enhancing cell-mediated immune response to tumours. The invention further provides anticancer combinations comprising a synthetic biological response modifier composition and one or more anticancer agents, wherein said combination improves the treatment of cancers over the composition or the anticancer agents alone.

Abstract: The invention provides methods for normalizing the sleep/wake cycle of a mammal by administering a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, uridine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound. As such the methods described herein may increase wakefulness, reduce tiredness or fatigue during the day, and improve sleep quality. The methods of the invention may also be used in the treatment of sleep disorders, such as insomnia, sleep apnea, periodic limb movements, restless leg syndrome, narcolepsy, and problem sleepiness, or for increasing cognitive function in sleep deprived individuals. Citicoline is an exemplary compound for use in the methods described herein.

Abstract: Cationic lipids having a derivatized quaternary ammonium head group that provide improved cell targeting ability and enhanced transfective efficacy for introducing molecules into cells are provided.

Abstract: A water treating system utilizes antimicrobial sand filter for killing bacteria and preventing microbial growth. Said antimicrobial sand filter consists of organic quaternary ammonium salt and inorganic metal compound.

Abstract: The two carbohydrate mixture of this invention utilizes a source of fructose in combination with at least one readily digestible glucose polymer source. The addition of the fructose significantly decreases the glycemic response when compared to the digestible glucose polymer alone. Additional components may be added to the simple two component carbohydrate mixture to form a carbohydrate system suitable for incorporation into an enteral nutritional. This carbohydrate system optionally incorporates nonabsorbent carbohydrates, dietary fiber and indigestible oligosaccharides. The present invention is also directed to an enteral nutritional which incorporates the two component carbohydrate mixture and less than 37% of calories from fat. Additionally, the invention is directed to a method of delivering nutrients to a person with diabetes by feeding the enteral nutritional.

Abstract: The invention relates to compounds of the general formula (I), as defined, and to pharmaceutical compositions containing them. The compounds of formula (I) are inhibitors of various lipid-related enzymes. They can be used in reducing accumulation of sphingolipids and thus in the treatment of lipid storage diseases. The compounds of formula (I) can also be used for the treatment of cancerous diseases and for killing of wild type and drug-resistant cancer cells.

Abstract: The use of one or more quaternary ammonium ester compositions to disinfect contact lenses and preserve ophthalmic lens compositions is described. Ophthalmic lens compositions containing one or more quaternary ammonium ester compositions and methods of making and using the same are also described.

Abstract: The invention provides aqueous disinfecting (germicidal) dip compositions comprising opacifying complexes formed by the reaction of cationic organic quaternary ammonium compounds (“quats”)and anionic organic sulfonates. The compositions are particularly useful as dairy cow teat dips. Complexes formed by the reaction of quats and organic sulfonates provide turbidity and opacity to these aqueous germicidal dip compositions. Such turbidity and opacity serve to enhance the visibility of the compositions, e.g., when applied to an animal's teat.

Abstract: The invention concerns a composition for a softening lotion which is liquid at a temperature of at least 5° C. and which is meant to be used in treating an absorbent paper product. In the invention, this composition comprises: (a) from 1 to 10% by wt. of a component essentially containing a quaternary ammonium compound; (b) from 5 to 99% by wt. of an aqueous emollient component which contains, as active substances: (i) one or more saturated linear fatty alcohols having at least 16 carbon atoms, (ii) one or more waxy esters having a total of at least 24 carbon atoms and, where called for, (iii) one or more nonionic and/or amphoteric emulsifiers; and (c) a balance to 100% by wt. of the required amount of a solvent of the type polyol, mineral oil or their mixtures. The invention relates to the manufacture of absorbent paper products.

Abstract: A compound of formula I:

Abstract: Disclosed are antimicrobial compositions comprising

Abstract: The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed.

Abstract: A topical delivery composition which employs a multivesicular emulsion in combination with a pharmaceutically/pharmacologically active agent is disclosed. The multivesicular emulsion is formed from a quaternary amine salt emulsifier such as behentrimonium methosulfate. The emulsion is multi-lamellar which is a series of concentric spheres or vesiculars of oil and water phase that can be seen microscopically. As a result, the active is time released over a sustained period rather than spike released as is common with most topicals.

Abstract: An enhancer composition for agricultural chemicals which can enhance the effectiveness of an agricultural chemical without causing any phytotoxicity to various crops, which comprises at least one nitrogen-containing compound selected from the group consisting of a tertiary amine, a tertiary amine salt and a quaternary ammonium salt and a chelating agent, wherein the content of the chelating agent ranges from 0.01 to 30 mol per mol of the nitrogen-containing compound.

Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.

Abstract: Methods of treating enveloped viruses with dialkyldialkylammonium halides are disclosed, along with associated pharmaceutical compositions.

Abstract: The present invention discloses an aqueous phenolates-containing liquid formulation having a solidification point of less than or equal to −10° C.

Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating to consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.

Abstract: The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat diseases associated with aberrant vascularization and methods of using pharmaceutical compositions of thiomolybdate derivatives to treat diseases associated with aberrant vascularization.

Abstract: The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-&kgr;B dysregulation and methods of using pharmaceutical compositions of thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-&kgr;B dysregulation.

Abstract: Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or sulfite compounds and/or thionate compounds and/or any organic, inorganic or organometallic precursors thereof. The unique compositions of this invention contain one or more “active sulfur compounds” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic compounds.

Abstract: The present invention is directed to a method for the disinfection and sterilization of material and surfaces contaminated with one or more members selected from the group consisting of bacteria and bacterial spores, comprising the steps of: (a) providing a biocidal fluid containing a mixture of effective amounts of a germinant and a germicide; and (b) contacting the material and surfaces contaminated with one or more members selected from the group consisting of bacteria and bacterial spores, with the biocidal fluid of step (a) for a time sufficient for disinfecting and sterilizing said material. The invention also provides a sterilizing composition suitable for killing and rendering spores lifeless comprising: (a) an effective amount of a germinating agent; (b) an effective amount of a germicide.

Abstract: A material and method for treating timber. The material comprises a preservative and a carrier. The carrier is selected such that it remains mobile within the wood and provides for migration of the preservative within the treated wood. By providing a carrier which is mobile within the wood, the timber has a ‘self healing’ effect wherein the carrier/preservative migrates to any freshly cut or exposed surface of the wood to thereby redistribute and treat such a surface within the preservative and hence maintain integrity of a treatment envelope surrounding the wood.

Abstract: Pressurized aerosol composition for administration by inhalation comprising a liquefied hydrofluoroalkane, a powdered medicament dispersed therein, and a suspending agent comprising a polymer soluble in the liquefied hydrofluoroalkane which is selected from polymers including recurring amide containing structural units, copolymers of amide containing units and carboxylic acid ester units, polyvinylacetate and acrylic acid/methacrylic acid ester copolymers.

Abstract: The present invention provides an antimicrobial composition. The composition comprises a cell-permeabilising agent and at least one compound of general formula (I) wherein R1 and R2 are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic fluorophilic; R3 and R4 are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy; R3 or R4+R2 can be saturated or an unsaturated cycloalkane; and “” represents a single bond or a double bond provided that at least one of R1, R2, R3 and R4 is a halogen.

Abstract: Methods are provided for preventing or inhibiting adverse cardiovascular effects associated with administration of a sympathetic nervous system antagonist in a subject, in which a subject in need thereof is administered a sympathetic nervous system antagonist and an endothelin antagonist. Methods for improving the efficacy of a sympathetic nervous system antagonist are also provided, comprising administering to a subject in need thereof a sympathetic nervous system antagonist together with an endothelin antagonist. Methods of treating prostate cancer or benign prostate hyperplasia (BPH) in a subject are also provided, in which a subject in need thereof is administered a sympathetic nervous system antagonist and an endothelin antagonist. The sympathetic nervous system antagonist may be an alpha-adrenoceptor antagonist, a ganglionic blocking agent or another inhibitor of the actions of the sympathetic nervous system.

Abstract: The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.

Abstract: Peptide compositions and methods for inhibiting and controlling the growth of microbes using peptides possessing antimicrobial activity are described. The composition comprises at least one antimicrobial peptide in combination with at least one biocide, germicide, preservative or antibiotic. The method comprises administering an amount of the peptide composition effective for the prevention, inhibition or termination of microbes in industrial and clinical settings.

Abstract: A method of dyeing and treating a substrate using a water-stabilized organosilane. A method of antimicrobially treating a food article. A method of antimicrobially coating a fluid container. A method of antimicrobially coating a latex medical article.

Abstract: The present invention relates to new medicament compositions based on anticholinergic compounds, which have a long-lasting effect, and salmeterol, processes for their production and their use in the therapy of respiratory ailments.

Abstract: The invention relates to compositions of a disinfectant agent containing a) at least one amine and/or quaternary ammonium salt of general formula (Ia) or (Ib), wherein R1 C6-18 represents alkyl, R2 represents benzyl or C6-18 alkyl; R3 C1-18 represents alkyl or —[(CH2)2—O)nR6 whereby n=1-20; R4 and R5 represent independently from each other C1-4 alkyl; R6 represents hydrogen or optionally substituted phenyl and A represents a monovalent anion or an equivalent multivalent anion of an inorganic or organic acid; and b) at least one guanidinium salt of formula (II), wherein X represents a monovalent anion or an equivalent multivalent anion of an organic or inorganic acid, in a mass ratio (I):(II) of 20:1-1:20. The inventive compositions are characterised in that they have a good bacterial and equally good fungicidal efficacy when used in low concentrations and can also be used as disinfectant agents as well as preservation agents.

Abstract: The present invention is directed to hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R1 to R8 and X are as defined herein.

Abstract: A method of treating living tissue includes applying to living tissue a biocompatible adhesive composition containing at least one alkyl ester cyanoacrylate monomer and a polymerization initiator or accelerator, wherein the polymerization initiator or accelerator is a quaternary amine.

Abstract: The present invention relates to a complex including colloid particles having an ion exchange capacity and having attached one or more ligands with a charge and a hydrophobic domain, and one or more pharmaceutical compounds associated with the colloid particles and/or the one or more ligands, as well as a method of making the complex. The present invention also relates to methods for preventing or reducing surface absorption or for delayed percutaneous delivery of one or more pharmaceutical compounds. The methods involve applying to a surface a complex according to the present invention. Another aspect of the present invention relates to a surface coated with colloid particles having attached one or more ligands with a charge and a hydrophobic domain and one or more pharmaceutical compounds associated with either or both of the colloid particles and the one or more ligands.

Abstract: A detergent such as nonionic, cationic or anionic detergents and preferably a “sugar detergent” such as octyl-glucopyranoside is rendered insoluble by being bound to an inert substrate. This detergent is effective at inactivating pathogens even when so bound. Under these conditions the concentration of detergent free in solution is vanishingly low: probably below one millimolar in concentration. Addition of insoluble detergent results in effective destruction of enveloped viruses in a variety of protein containing solutions such as blood, plasma, clotting factors or other proteins purified from human blood. Because the detergent is essentially entirely bound to the solid substrate, there is little or no difficulty in ensuring that the end product is detergent-free. Because the detergent is so bound, it causes essentially no damage to proteins, blood cells and other cellular material.

Abstract: A polymeric composition having antimicrobial properties and a process for rendering the surface of a substrate antimicrobial are disclosed. The composition comprises a crosslinked chemical combination of (i) a polymer having amino group-containing side chains along a backbone forming the polymer, (ii) an antimicrobial agent selected from quaternary ammonium compounds, gentian violet compounds, substituted or unsubstituted phenols, biguanide compounds, iodine compounds, and mixtures thereof, and (iii) a crosslinking agent containing functional groups capable of reacting with the amino groups.

Abstract: Antimicrobial compositions having synergistic combinations of octoxyglycerin and at least one other antimicrobial agent in formulations which are more effective than prior art compositions without causing increased irritation to the skin of the average user. In certain embodiments, skin irritation may be minimized by low concentrations of antimicrobials and/or the presence of soothing compounds such as zinc. Preferred embodiments include combinations of octoxyglycerin, a quaternary compound, and at least one other antimicrobial agent. Without being bound to any particular theory, it is hypothesized that the unexpected antimicrobial effectiveness of combinations of octoxyglycerin may result from an enhancement of the permeability of microbes to antimicrobials caused by octoxyglycerin.

Abstract: An ophthalmic solution or contact lens solution comprising at least one germicidal/preservative component. The ophthalmic solution further comprises at least one selected amino-acid-based component, 0-0.2 wt. % of sodium chloride, and 0-0.5 wt. % of phosphate. The contact lens solution further comprises at least one selected acidic component and 0-0.2 wt. % of sodium chloride. Alternatively, the contact lens solution further comprises at least one selected amino-acid-based component, at least one selected acidic compound, and 0-0.2 wt. % of sodium chloride.

Abstract: The invention relates to the use of nanoscalar, cationic compounds with particle diameters of between 10 and 300 nm for producing cosmetic and/or pharmaceutical preparations.